A promising inactivated whole-virion SARS-CoV-2 vaccine

Type Journal Article Author Irina Isakova-Sivak Author Larisa Rudenko URL https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30832-X/abstract Publication The Lancet Infectious Diseases ISSN 1473-3099, 1474-4457 Date 15/10/2020 Extra Publisher: Elsevier PMID: 33069282 Journal Abbr The Lancet Infectious Diseases DOI 10.1016/S1473-3099(20)30832-X Library Catalog www.thelancet.com Language English Abstract The ongoing COVID-19 pandemic is the only outbreak to date in which the time from identification of a pathogen to the presentation of the first clinical trial results for a specific vaccine against the pathogen was less than 9 months. By September, 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine landscape included 39 candidates being tested in clinical trials and more than 200 candidates in preclinical development.1 It is generally accepted that only vaccines can halt the spread of the pandemic virus; thus, several groups have already published interim results of phase 1/2 clinical trials of SARS-CoV-2 vaccines generated on various vaccine platforms.